Department of Clinical Sciences Lund, Division of Infection Medicine, Lund University, Lund, Sweden.
Bandim Health Project, Indepth Network, Bissau, Guinea-Bissau; Department of Clinical Immunology, Aarhus University Hospital, Aarhus, Denmark.
J Virol Methods. 2019 Jun;268:42-47. doi: 10.1016/j.jviromet.2019.03.005. Epub 2019 Mar 11.
Being able to discriminate between HIV-1, HIV-2 and HIV-1/2 dual infection is imperative for the appropriate selection of antiretroviral therapy (ART) in regions with high HIV-2 endemicity.
To evaluate Bio-Rad Geenius HIV-1/2 Confirmatory Assay against INNO-LIA HIV 1/2 Score and ImmunoComb HIV 1/2 BiSpot with an emphasis towards ability to discriminate between HIV-1, HIV-2 and HIV-1/2 dual infection.
131 samples from ART naïve HIV infected patients in Guinea-Bissau were selected retrospectively and tested with Geenius, INNO-LIA and Immunocomb. HIV-1/2 RNA were measured in all samples and HIV-1/2 DNA in 59 samples.
The Geenius reader typed 62 samples as HIV-1 reactive, 37 samples as HIV-2 reactive and 32 samples as HIV-1/2 dually reactive. Geenius manual reading classified 10% more samples as HIV-1/2 dually reactive (n = 35). INNO-LIA typed 63 samples as HIV-1 reactive, 36 samples as HIV-2 reactive and 32 samples as HIV-1/2 dually reactive while Immunocomb classified a large proportion of samples as HIV-1/2 dually reactive (n = 45). The measurement of agreement of the Geenius reader compared with INNO-LIA and Immunocomb was 92.4% and 84.0% respectively while the measurement of agreement of Geenius manual reading compared with INNO-LIA and Immuncomb was 93.1% and 89.3% respectively.
Geenius has similar performance characteristics as INNO-LIA, and performs considerably better than Immunocomb, for differentiating between HIV types. This is especially true when using the Geenius reader while manual reading of the Geenius assay seemed to overestimate the numbers of HIV-1/2 dually reactive samples.
在 HIV-2 流行地区，能够区分 HIV-1、HIV-2 和 HIV-1/2 双重感染对于适当选择抗逆转录病毒疗法 (ART) 至关重要。
评估 Bio-Rad Geenius HIV-1/2 确认检测与 INNO-LIA HIV 1/2 Score 和 ImmunoComb HIV 1/2 BiSpot 的性能，重点是区分 HIV-1、HIV-2 和 HIV-1/2 双重感染的能力。
回顾性选择来自几内亚比绍的 131 名接受 ART 的 HIV 感染患者的样本，用 Geenius、INNO-LIA 和 Immunocomb 进行检测。所有样本均检测 HIV-1/2 RNA，59 份样本检测 HIV-1/2 DNA。
Geenius 阅读器将 62 份样本归类为 HIV-1 反应性，37 份样本归类为 HIV-2 反应性，32 份样本归类为 HIV-1/2 双重反应性。Geenius 手动阅读将 10%的样本归类为 HIV-1/2 双重反应性 (n=35)。INNO-LIA 将 63 份样本归类为 HIV-1 反应性，36 份样本归类为 HIV-2 反应性，32 份样本归类为 HIV-1/2 双重反应性，而 Immunocomb 将很大比例的样本归类为 HIV-1/2 双重反应性 (n=45)。与 INNO-LIA 和 Immunocomb 相比，Geenius 阅读器的一致性测量分别为 92.4%和 84.0%，而 Geenius 手动阅读与 INNO-LIA 和 Immuncomb 的一致性测量分别为 93.1%和 89.3%。
与 INNO-LIA 相比，Geenius 具有相似的性能特征，并且在区分 HIV 型别方面表现明显优于 Immunocomb。当使用 Geenius 阅读器时尤其如此，而 Geenius 检测的手动阅读似乎高估了 HIV-1/2 双重反应性样本的数量。
